2023 World Conference on Lung Cancer (Posters)-P2.17. Anti-PD-L1 Therapy Failed to Reduce the Risk of Developing Brain Metastases in Patients with ES-SCLC

P2.17. Anti-PD-L1 Therapy Failed to Reduce the Risk of Developing Brain Metastases in Patients with ES-SCLC - PDF(Abstract)

Back to course

Pdf Summary

A retrospective study presented at the WCLC 2023 conference evaluated the effectiveness of anti-PD-L1 therapy in reducing the risk of developing brain metastases in patients with extensive-stage small cell lung cancer (ES-SCLC). The study included 250 patients who were divided into groups based on the presence of baseline brain metastases and first-line treatment modalities. The overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS), and cumulative incidence of brain metastases were analyzed.<br /><br />The results showed that the addition of PD-L1 inhibitors prolonged the overall median OS for all patients, regardless of the presence of brain metastases. Patients with baseline brain metastases also benefited from anti-PD-L1 therapy in terms of survival. However, immunotherapy did not delay the median time to develop brain progression or reduce the risk of intracranial metastases in patients without baseline brain metastases.<br /><br />The study highlights the overall survival benefit of anti-PD-L1 therapy in ES-SCLC patients, including those with brain metastases. However, it suggests that immunotherapy may not be effective in preventing the development of brain metastases in patients without baseline brain metastases. The presence of brain metastases did not have a predictive correlation with overall survival.<br /><br />These findings have important clinical implications for the management of brain metastases from ES-SCLC, especially in the era of immunotherapy. The study emphasizes the need for further research and personalized treatment approaches for patients with ES-SCLC with and without brain metastases.

Asset Subtitle

Hui Zhu

Meta Tag

Speaker Hui Zhu

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

retrospective study

WCLC 2023 conference

anti-PD-L1 therapy

brain metastases

ES-SCLC

overall survival

immunotherapy

baseline brain metastases

first-line treatment modalities

clinical implications